By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Domainex Ltd 

324 Cambridge Science Park

Cambridge    CB4 0WG  United Kingdom
Phone: 44-0-1993-201801 Fax: n/a



Company News
Domainex Ltd Announces The Grant Of US And European Patents For Its Lead Programme, Targeting IKK Epsilon And TBK1 For The Treatment Of Diseases Such As COPD And Psoriasis 5/11/2015 9:55:28 AM
Domainex Ltd Prepares For Expansion As It Announces The Appointment Of Barry Knight As Chief Financial Officer And Company Secretary, And Thomas Mander As Chief Operating Officer 4/8/2015 9:48:50 AM
ZoBio And Domainex Ltd Join Forces To Deliver Crucial Drug Target Information To Support FORMA Therapeutics, Inc.’ Drug Discovery Programs 12/8/2014 10:15:00 AM
Domainex Ltd Reports Success Of Its Lead Compound In Pre-Clinical Model Of COPD And Secures £1.4 Million Biomedical Catalyst Award 7/9/2014 10:30:11 AM
Domainex Ltd Programme Shows Great Promise For The Treatment Of Inflammatory Diseases, Such As Chronic Obstructive Pulmonary Disease (COPD) 4/7/2014 3:06:27 PM
University of Warwick Wins Domainex Ltd's First Discovery STAR Award to Support Hunt for New Chagas Disease Treatment 9/3/2013 8:54:08 AM
Domainex Ltd Announces Investment Round to Progress Its TBK1/IKKe and Epigenetic Programs 2/14/2013 10:21:02 AM
Domainex Ltd Launches Discovery STAR Award to Support Early Academic Drug Discovery 1/22/2013 11:10:06 AM
Domainex Ltd Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling 11/5/2012 12:01:39 PM
UCB, Inc. (UCBJF.PK) and Domainex Ltd Collaboration Provides Valuable Information on Cancer Drug Target 3/12/2012 11:03:55 AM